The fight against HIV/AIDS is at a critical juncture, and the potential for an effective vaccine is a beacon of hope. A vaccine could be the game-changer we've been waiting for.
On December 2, 2025, the International AIDS Vaccine Initiative (IAVI) and the International AIDS Society (IAS) released a compelling advocacy brief, highlighting the promise of sustained investment in HIV vaccine research. This brief outlines a strategic path forward, emphasizing the need for advanced clinical trials, efficient research methodologies, and inclusive practices.
But here's where it gets controversial: the brief also underscores the importance of regional vaccine research and manufacturing ecosystems. Should global efforts be centralized, or is a decentralized approach more effective? It's a question that sparks debate among experts.
Access the full advocacy brief here.
On the same day, the World Health Organization (WHO) emphasized the critical role of new prevention tools and investment in services in the ongoing battle against AIDS. This sentiment was echoed by amfAR, who stressed the continued importance of focusing on key populations affected by HIV/AIDS and co-infections.
In a significant development, the Unitaid partnership with Wits RHI and Fiocruz has initiated the use of Lenacapavir in South Africa and Brazil. This collaboration is a testament to the global effort to combat HIV/AIDS and co-infections.
If you're living with HIV/AIDS, part of an affected community, or working/volunteering in this field, your involvement is crucial. Join us, support our cause, and help shape the future of HIV/AIDS prevention and treatment.
Get involved:
- Become a member
- Support our work
Stay informed with the EATG newsletter and HIV & co-infections bulletin. Subscribe to receive regular updates and stay connected to the latest news and developments in the field.
Subscribe to our newsletters:
- EATG Newsletter
- HIV&Co-infections Bulletin
Let's work together to make a difference and bring an end to HIV/AIDS.
